Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Maha, Elgaafary"'
Autor:
Y. El Miedany, Hala Lotfy, Laila A.G. Hegazy, Maha Elgaafary, Safaa Mahran, Susan Plummer, Walaa Elwakil
Publikováno v:
Egyptian Rheumatology and Rehabilitation, Vol 51, Iss 1, Pp 1-17 (2024)
Abstract Background The objectives of this work were as follows: (1) to develop holistic recommendations for physical activity, sleep, sedentary behaviours and eating habits adapted to children and adolescent life stage (5–17 years) and targeting o
Externí odkaz:
https://doaj.org/article/9fc3f0ff8b08473a9b9849efc90bf15f
Autor:
Yasser El Miedany, Maha Elgaafary, Naglaa Gadallah, Safaa Mahran, Mohammed Hassan Abu-Zaid, Waleed Hassan, Walaa Elwakil
Publikováno v:
Egyptian Rheumatology and Rehabilitation, Vol 51, Iss 1, Pp 1-8 (2024)
Abstract Background Gender differences in the diagnosis and treatment of osteoporosis is a relatively common phenomenon, particularly amongst those patients under 80 years of age presenting with fragility fractures. The clinical implications of these
Externí odkaz:
https://doaj.org/article/39a4bb8acc3042d18960579d6b986b74
Autor:
Yasser El Miedany, Naglaa Ali Gadallah, Mathias Toth, Waleed Hassan, Maha Elgaafary, Mohamed Hassan, Mervat Eissa, Sally Saber, Walaa Elwakil, Safaa Mahran
Publikováno v:
Egyptian Rheumatology and Rehabilitation, Vol 49, Iss 1, Pp 1-7 (2022)
Abstract Background This is a Clinical Practice Guideline update released by the Egyptian Academy of Bone Health and Metabolic Bone Diseases. It does not replace the clinical practice guidelines published for the treatment of osteoporosis in 2021, bu
Externí odkaz:
https://doaj.org/article/83b70d74fc354650b7d04411392c46b3
Autor:
Hany M. Dabbous, Manal H. El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-
Externí odkaz:
https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d0
Autor:
Hany M. Dabbous, Manal H. El‑Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/4b565f65ac4a46f0bd15948e52f78885
Autor:
Hany Dabbous, Mahmoud M Mahmoud, Maha Elgaafary, Mohamed Eltabbakh, Rana M Taha, Ahmed T Elganzory, Ahmed F Sherief, Amal Mi Goda
Publikováno v:
Acta Scientific Microbiology. 4:31-37
Autor:
Fatma F S Ebeid, Manal H El-Sayed, Gihan El Assal, Ahmed R Riad, Sahar M Hassany, Hany Dabbous, Hesham Elghazaly, Mohamed Awad Tageldin, Maha Elgaafary, Ahmed F Sherief, Ehab Fawzy
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle
Autor:
Sally Adel Hakim, Amr Hassan, Mervat Rady, Wafaa Mohamed Hussein, Maha M. Wahdan, Wagida A, Ghada Wassif, Dalia G. Sos, Maha Elgaafary, Mohammed Y. El-Awady
Publikováno v:
Al-Azhar Medical Journal. 49:305-318
Background: Marriage timing is one of the important determinants of birth rates and health profile of both the mothers and infants. Child marriage is recognized as a major development issue that affects girls in many developing countries. The practic
Autor:
Manal H El-Sayed, Gihan El Assal, Hany Dabbous, Hesham Elghazaly, Ehab Fawzy, Maha Elgaafary, Fatma Fs Ebeid, Ahmed R Riad, Mohamed Awad Tageldin, Ahmed F Sherief, Sahar M Hassany
Background: Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases.Methods: A rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3d34b2ebcd2069dbeb3450763873d9
https://doi.org/10.21203/rs.3.rs-83677/v1
https://doi.org/10.21203/rs.3.rs-83677/v1
Autor:
Hany M, Dabbous, Manal H, El-Sayed, Gihan, El Assal, Hesham, Elghazaly, Fatma F S, Ebeid, Ahmed F, Sherief, Maha, Elgaafary, Ehab, Fawzy, Sahar M, Hassany, Ahmed R, Riad, Mohamed A, TagelDin
Publikováno v:
Scientific reports. 11(1)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle